Zobrazeno 1 - 10 of 178 pro vyhledávání: '"E. Malacco"'
1
Akademický článek
ANTIHYPERTENSIVE EFFICACY AND SAFETY OF OLMESARTAN MEDOXOMIL AND RAMIPRIL IN ELDERLY PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION: THE ESPORT STUDY
Autor: E. Malacco, S. Omboni, M. Volpe, A. Auteri, A. Zanchetti
Publikováno v: Российский кардиологический журнал, Vol 0, Iss 1, Pp 52-62 (2012)
Objective. To compare the efficacy and safety of the angiotensin II antagonist olmesartan medoxomil (O) and the ACE inhibitor ramipril (R) in elderly patients with essential arterial hypertension. Methods. After a 2-week placebo wash-out 1102 treated
Externí odkaz: https://doaj.org/article/3169e15704ad4e1d90e9b0a038360163
Zobrazit plný text záznamu
2
Akademický článek
ZOFENOPRIL PLUS HYDROCHLOROTHIAZIDE COMBINATION THERAPY FOR THE TREATMENT OF MILD TO MODERATE HYPERTENSION
Autor: A. Zanchetti, G. Parati, E. Malacco
Publikováno v: Российский кардиологический журнал, Vol 0, Iss 5, Pp 81-88 (2011)
Достижение целевых уровней артериального давления (АД) в условиях повседневной клинической практики представляет собой одну из наибол
Externí odkaz: https://doaj.org/article/ad1b11276408435b869f201599567a00
Zobrazit plný text záznamu
3
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis
Autor: Milad Nazarzadeh, Zeinab Bidel, Dexter Canoy, Emma Copland, Derrick A Bennett, Abbas Dehghan, George Davey Smith, Rury R Holman, Mark Woodward, Ajay Gupta, Amanda I Adler, Malgorzata Wamil, Naveed Sattar, William C Cushman, Richard J McManus, Koon Teo, Barry R Davis, John Chalmers, Carl J Pepine, Kazem Rahimi, L Agodoa, A Algra, F W Asselbergs, N Beckett, E Berge, H Black, F P J Brouwers, M Brown, C J Bulpitt, B Byington, J Cutler, R B Devereaux, J Dwyer, R Estacio, R Fagard, K Fox, T Fukui, Y Imai, M Ishii, S Julius, Y Kanno, S E Kjeldsen, J Kostis, K Kuramoto, J Lanke, E Lewis, J Lewis, M Lievre, L H Lindholm, S Lueders, S MacMahon, G Mancia, M Matsuzaki, M H Mehlum, S Nissen, H Ogawa, T Ogihara, T Ohkubo, C Palmer, A Patel, M Pfeffer, N R Poulter, H Rakugi, G Reboldi, C Reid, G Remuzzi, P Ruggenenti, T Saruta, J Schrader, R Schrier, P Sever, P Sleight, J A Staessen, H Suzuki, L Thijs, K Ueshima, S Umemoto, W H van Gilst, P Verdecchia, K Wachtell, P Whelton, L Wing, Y Yui, S Yusuf, A Zanchetti, Z Y Zhang, C Anderson, C Baigent, BM Brenner, R Collins, D de Zeeuw, J Lubsen, E Malacco, B Neal, V Perkovic, B Pitt, A Rodgers, P Rothwell, G Salimi-Khorshidi, J Sundström, F Turnbull, G Viberti, J Wang
Publikováno v: Nazarzadeh, M, Bidel, Z, Canoy, D, Copland, E, Bennett, D A, Dehghan, A, Davey Smith, G, Holman, R R, Woodward, M, Gupta, A, Adler, A I, Wamil, M, Sattar, N, Cushman, W C, McManus, R J, Koon, T, Davis, B R, Chalmers, J, Pepine, C J & Rahimi, K 2022, ' Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes : an individual participant-level data meta-analysis ', Lancet Diabetes and Endocrinology, vol. 10, no. 9, pp. 645-654 . https://doi.org/10.1016/S2213-8587(22)00172-3
Background Controversy exists as to whether the threshold for blood pressure-lowering treatment should differ between people with and without type 2 diabetes. We aimed to investigate the effects of blood pressure-lowering treatment on the risk of maj
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44422d6b20717ea24c63a10d59c54203
https://pubmed.ncbi.nlm.nih.gov/36427521
Zobrazit plný text záznamu
4
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis
Autor: Emma Copland, Dexter Canoy, Milad Nazarzadeh, Zeinab Bidel, Rema Ramakrishnan, Mark Woodward, John Chalmers, Koon K Teo, Carl J Pepine, Barry R Davis, Sverre Kjeldsen, Johan Sundström, Kazem Rahimi, A Adler, L Agodoa, A Algra, F W Asselbergs, N Beckett, E Berge, H Black, F P J Brouwers, M Brown, C J Bulpitt, B Byington, J Chalmers, W C Cushman, J Cutler, B R Davis, R B Devereaux, J Dwyer, R Estacio, R Fagard, K Fox, T Fukui, A K Gupta, R R Holman, Y Imai, M Ishii, S Julius, Y Kanno, S E Kjeldsen, J Kostis, K Kuramoto, J Lanke, E Lewis, J Lewis, M Lievre, L H Lindholm, S Lueders, S MacMahon, G Mancia, M Matsuzaki, M H Mehlum, S Nissen, H Ogawa, T Ogihara, T Ohkubo, C Palmer, A Patel, C J Pepine, M Pfeffer, N R Poulter, H Rakugi, G Reboldi, C Reid, G Remuzzi, P Ruggenenti, T Saruta, J Schrader, R Schrier, P Sever, P Sleight, J A Staessen, H Suzuki, L Thijs, K Ueshima, S Umemoto, W H van Gilst, P Verdecchia, K Wachtell, P Whelton, L Wing, M Woodward, Y Yui, S Yusuf, A Zanchetti, Z Y Zhang, C Anderson, C Baigent, BM Brenner, R Collins, D de Zeeuw, J Lubsen, E Malacco, B Neal, V Perkovic, B Pitt, A Rodgers, P Rothwell, G Salimi-Khorshidi, J Sundström, F Turnbull, G Viberti, J Wang
Findings 33 trials met the inclusion criteria, and included 260 447 participants with 15 012 cancer events. Median follow-up of included participants was 4?2 years (IQR 3?0?5?0). In the individual participant data meta-analysis comparing each drug cl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03bf241456fba8c60d821c06d95aca03
http://hdl.handle.net/10044/1/89099
Zobrazit plný text záznamu
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Evening vs morning isradipine sustained release in essential hypertension: a double-blind study with 24 h ambulatory monitoring
Autor: Massimo Milani, E Malacco, F. Tettamanti, Roberto Fogari, A. E. Gnemmi
Publikováno v: British Journal of Clinical Pharmacology. 35:51-54
A randomized, double-blind, placebo controlled study evaluated the effects on 24 h ambulatory blood pressure (ABP) of isradipine sustained release (I-SRO) administered once daily, in the morning (AM) or in the evening (PM). Eighteen uncomplicated ess
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::803fc57e3914ee9645267511a60c4731
https://doi.org/10.1111/j.1365-2125.1993.tb05670.x
Zobrazit plný text záznamu
10
Nebivolol/hydrochlorothiazide (HCTZ) combination in patients with essential hypertension: a pooled analysis from five non-interventional studies with a focus on diabetic and elderly patients
Autor: E, Malacco
Publikováno v: European review for medical and pharmacological sciences. 14(5)
Nebivolol is a third-generation beta-blocker, characterized by unique pharmacological properties. The combination of nebivolol and hydrochlorothiazide (HCTZ) has been evaluated in large-scale clinical trials. This post-marketing surveillance analysis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::20601ff31de4802e057fec79c41a60b8
https://pubmed.ncbi.nlm.nih.gov/20556921
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje